Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 175

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 175
---
 net sales of € 227 million in 2023 , up 10.0% CER, reflecting increased awareness of acquired thrombotic thrombo- cytopenic purpura (aTTP), and treatment in line with guidelines from the International Society on Thrombosis and Haemostasis (ISTH) recommending first-line use of Cablivi for all aTTP patients. Sales reached € 112 million in the United States (+ 4.5% CER), and in Europe net sales were up 4.3% CER at € 98 million, mainly due to greater market penetration as a result of increased product awareness. Xenpozyme reported net sales of € 91 million, mainly in the United States (€ 52 million) and Europe (€ 31 million) . Net sales of Enjaymo reached € 72 million, with sales being generated primarily in the United States and Japan. In the second quarter of 2023, Sanofi acquired Provention, adding Tzield , an innovative first-in-class treatment for people with type 1 diabetes, to the core medicines portfolio. In 2023 , Tzield sales were €25 million, in line with the expected gradual ramp-up as a result of early patient identification programs. Immunology & Inflammation Dupixent (developed in collaboration with Regeneron) generated net sales of € 10,715 million in 2023 , up 29.2% on a reported basis and 34.0% at CER. In the United States, sales of Dupixent reached € 8,145 million in 2023 , up 32.6% CER, boosted by continuing strong demand in the product's approved indications: atopic dermatitis, asthma, nasal polyps, eosinophilic esophagitis, and prurigo nodularis. In Europe, the product posted 2023 net sales of € 1,224 million, up 30.9% CER, driven by continuing growth in atopic dermatitis, asthma and nasal polyps. In the Rest of the World region, Dupixent posted net sales of € 1,346 million ( +46.2% CER), driven mainly by Japan and China. Other medicines Lantus sales fell to € 1,420 million ( -32.0% CER) in 2023 . In the United States, sales were down 62.6% CER